Residual adrenal function in Autoimmune Addison’s Disease—effect of dual therapy with rituximab and depot tetracosactide
JournalJournal of Clinical Endocrinology & Metabolism
MetadataShow full item record
In autoimmune Addison's disease (AAD), exogenous glucocorticoid (GC) therapy is an imperfect substitute for physiological GC secretion. Patients on long-term steroid replacement have increased morbidity, reduced life expectancy, and poorer quality of life.